Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Cipla
Federal Trade Commission
McKesson
Farmers Insurance
Dow
US Department of Justice
Boehringer Ingelheim
Cantor Fitzgerald
Moodys
Fish and Richardson

Generated: August 20, 2017

DrugPatentWatch Database Preview

Details for Patent: ► Subscribe

« Back to Dashboard

Details for Patent: ► Subscribe

Title:Pharmaceutical compositions of Cefixime
Abstract: A pharmaceutical suspension formulation comprising a dose greater than 100 mg/5 ml Cefixime and pharmaceutically acceptable excipients.
Inventor(s): Wagh; Sanjay Chhagan (Pune, IN), Metkar; Bharat Raghunath (Pune, IN), Avachat; Makarand Krishnakumar (Pune, IN), Sen; Himadri (Pune, IN)
Assignee: LUPIN LIMITED (Mumbai, IN)
Filing Date:Mar 23, 2007
Application Number:12/297,026
Claims:1. A suspension dosage form of Cefixime comprising: a unit dose of 200 mg/5 ml of Cefixime; 0.4 wt-% xanthan gum; and 1 wt-% colloidal silicon dioxide; wherein said suspension dosage form is bioequivalent to the commercially available Cefixime suspension formulation of 2.times.100 mg/5 ml.

2. The suspension dosage form of claim 1, further comprising a pharmaceutically acceptable excipient; the pharmaceutically acceptable excipient selected from sweetener, flavoring agent, preservative, or mixture thereof.

3. The suspension dosage form of claim 2, wherein the sweetener is mannitol, sorbitol sodium saccharine, sodium cyclamate, or aspartame.

4. The suspension dosage form of claim 2, wherein the flavoring agent is strawberry flavor, banana flavor, or artificial cream flavor.

5. The suspension dosage form of claim 2, wherein the preservative is sodium benzoate, benzoic acid, ethylenediaminetetraacetic acid, sorbic acid, benzethonium chloride, benzalkonium chloride, bronopol, butyl paraben, methyl paraben, ethylparaben, propyl paraben, thiomerosol, sodium propionate, chlorhexidine, chlorobutanol, chlorocresol, cresol, imidurea, phenol, phenylmercuric salts, potassium sorbate, propylene glycol, or mixtures thereof.

6. A method of treating a subject having acute bacterial otitis media, pharyngitis, tonsillitis, acute bronchitis, or chronic bronchitis, the method comprising: administering to the subject the oral suspension dosage form of claim 1.

7. A method of treating a subject having an uncomplicated urinary tract infection, gonorrhea, or both, the method comprising: administering to the subject the oral suspension dosage form of claim 1.

8. The suspension dosage form of claim 1, further comprising 0.4 wt-% sodium benzoate.

9. A suspension dosage form of Cefixime consisting of: a unit dose of 200 mg/5 ml of Cefixime; 0.4 wt-% xanthan gum; 1 wt-% colloidal silicon dioxide; and sweetener, flavoring agent, preservative, or mixture thereof; wherein said suspension dosage form is bioequivalent to the commercially available Cefixime suspension formulation of 2.times.100 mg/5 ml.

10. The suspension dosage form of claim 9, wherein the sweetener is mannitol, sorbitol sodium saccharine, sodium cyclamate, or aspartame.

11. The suspension dosage form of claim 9, wherein the flavoring agent is strawberry flavor, banana flavor, or artificial cream flavor.

12. The suspension dosage form of claim 9, wherein the preservative is sodium benzoate, benzoic acid, ethylenediaminetetraacetic acid, sorbic acid, benzethonium chloride, benzalkonium chloride, bronopol, butyl paraben, methyl paraben, ethylparaben, propyl paraben, thiomerosol, sodium propionate, chlorhexidine, chlorobutanol, chlorocresol, cresol, imidurea, phenol, phenylmercuric salts, potassium sorbate, propylene glycol, or mixtures thereof.

13. The suspension dosage form of claim 9, wherein the preservative is 0.4 wt-% sodium benzoate.

14. A method of treating a subject having acute bacterial otitis media, pharyngitis, tonsillitis, acute bronchitis, or chronic bronchitis, the method comprising: administering to the subject the suspension dosage form of claim 9.

15. A method of treating a subject having an uncomplicated urinary tract infection, gonorrhea, or both, the method comprising: administering to the subject the suspension dosage form of claim 9.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Federal Trade Commission
Boehringer Ingelheim
McKesson
Farmers Insurance
Express Scripts
Chinese Patent Office
UBS
Cipla
Novartis
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot